Published in Biotech Business Week, March 28th, 2005
ATLAS is the first trial using Boston Scientific's new Liberte coronary stent as a platform for its paclitaxel-eluting coronary stent system. Taxus Liberte is the next generation to Boston Scientific's first paclitaxel-eluting coronary stent system, Taxus Express, which is the worldwide leader in the coronary stent market today.
The ATLAS trial is a global, multicenter pivotal study designed to support U.S. Food and Drug Administration approval of the Taxus Liberte stent system. It is...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.